Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H31F3N8O2 |
| Molecular Weight | 568.5933 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN(C)C1=NC(OCC(F)(F)F)=C(NC2=NC=CC(=N2)C3=CN(C)C4=C3C=CC=C4)C=C1NC(=O)C=C
InChI
InChIKey=GHKOONMJXNWOIW-UHFFFAOYSA-N
InChI=1S/C28H31F3N8O2/c1-6-24(40)33-21-15-22(26(41-17-28(29,30)31)36-25(21)38(4)14-13-37(2)3)35-27-32-12-11-20(34-27)19-16-39(5)23-10-8-7-9-18(19)23/h6-12,15-16H,1,13-14,17H2,2-5H3,(H,33,40)(H,32,34,35)
| Molecular Formula | C28H31F3N8O2 |
| Molecular Weight | 568.5933 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.37 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
20 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
34.3 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
80.4 ng/mL |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
110 ng/mL |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.4 ng/mL |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
33.7 ng/mL |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
61.2 ng/mL |
80 mg 1 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
92.3 ng/mL |
160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
120 ng/mL |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
25.4 ng/mL CLINICAL TRIAL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
39.6 ng/mL CLINICAL TRIAL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
99.5 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
276 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
473 ng × h/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1060 ng × h/mL |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1610 ng × h/mL |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
316 ng × h/mL |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
585 ng × h/mL |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1050 ng × h/mL |
80 mg 1 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1640 ng × h/mL |
160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2020 ng × h/mL |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
843 ng × h/mL CLINICAL TRIAL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1110 ng × h/mL CLINICAL TRIAL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
34.9 h CLINICAL TRIAL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
34.1 h CLINICAL TRIAL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5% |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALFLUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 03:12:14 GMT 2025
by
admin
on
Wed Apr 02 03:12:14 GMT 2025
|
| Record UNII |
A49A7A5YN4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
118861389
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY | |||
|
A49A7A5YN4
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY | |||
|
300000039589
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY | |||
|
MN-160
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY | |||
|
1869057-83-9
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY | |||
|
C180535
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY | |||
|
12503
Created by
admin on Wed Apr 02 03:12:14 GMT 2025 , Edited by admin on Wed Apr 02 03:12:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ? 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ? 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
IC50
|
||
|
TARGET -> INHIBITOR |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ? 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
IC50
|
||
|
METABOLIC ENZYME -> INDUCER |
Similar to rifampin in its potency to induce CYP3A4
MAJOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| BRAIN/PLASMA RATIO | PHARMACOKINETIC |
|
||||
| Biological Half-life | PHARMACOKINETIC |
|